Amerco
Change company Symbol lookup
Select an option...
UHAL Amerco
NBRV Nabriva Therapeutics PLC
HRB H & R Block Inc
GM General Motors Co
NDAQ Nasdaq Inc
DYYXF DB Commodity Double Long ETN
KIQ Kelso Technologies Inc
MMM 3M Co
CBOE Cboe Global Markets Inc
PFE Pfizer Inc
Go

Industrials : Road & Rail | Mid Cap Blend
Company profile

AMERCO is a do-it-yourself moving and storage operator through its subsidiary, U-Haul International, Inc. (U-Haul). The Company supplies its products and services to help people move and store their household and commercial goods through U-Haul. It sells U-Haul brand boxes, tape, and other moving and self-storage products and services to do-it-yourself moving and storage customers at its distribution outlets and through uhaul.com and eMove Websites. The Company operates through three segments: Moving and Storage; Property and Casualty Insurance, and Life Insurance. The Moving and Storage segment includes the operations of AMERCO, U-Haul and Amerco Real Estate Company, and the subsidiaries of U-Haul and Real Estate. The Property and Casualty Insurance segment consists of the operations of Repwest Insurance Company and its subsidiaries, and ARCOA Risk Retention Group. The Life Insurance segment consists of the operations of Oxford Life Insurance Company and its subsidiaries.

Price
Delayed
$302.46
Day's Change
7.26 (2.46%)
Bid
--
Ask
--
B/A Size
--
Day's High
303.69
Day's Low
297.42
Volume
(Light)

Today's volume of 17,797 shares is on pace to be much lighter than UHAL's 10-day average volume of 41,291 shares.

17,797

UPDATE: HHS: States to dispense Gilead's remdesivir to hospitals

3:42 pm ET May 11, 2020 (MarketWatch)
Print

The Department of Health and Human Services on Saturday said the states with the greatest number of COVID-19 cases have been allotted doses of Gilead Sciences Inc.'s (GILD) remdesivir based on their case counts. Some clinical groups last week had raised concerns (http://www.marketwatch.com/story/infectious-disease-doctors-ask-government-to-explain-how-it-decides-who-gets-gileads-remdesivir-2020-05-07) about what hospitals and patients will have access to the drug, which is the first new medication to receive an authorization from the Food and Drug Administration as a COVID-19 therapy. Gilead has donated 1.5 million doses of the drug, which HHS is dispensing to states, which are then allocating to hospitals. Illinois (140 cases of remdesivir), New York (565 cases), New Jersey (110 cases), and Massachusetts (117 cases) have been allotted the most number of cases, each of which has 40 vials of remdesivir. The FDA granted an [l: emergency use authorization (http://www.marketwatch.com/story/how-gileads-remdesivir-became-the-leader-in-the-rush-to-find-a-treatment-for-covid-19-2020-05-01) to Gilead for remdesivir on May 1. Gilead's stock has gained 19.5% year-to-date, while the S&P 500 is down 9.3%.%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

May 11, 2020 15:42 ET (19:42 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.